Life sciences and diagnostics company Danaher is moving focus on the growth opportunities for Life Sciences and Diagnostics segments. The company intends to float off its Environmental & Applied Solutions (EAS) segment into a separate publicly traded company. DHR would then be to further capitalize on the seen powerful growth in the other segments having been entrenched in the development of COVID-19 vaccines and therapeutics through its $21.4 bln acquisition of Cytiva in 2020. Cepheid also received Emergency Use Authorization … Continue reading “Danaher Floating off Environmental & Applied Solutions Segment Enhances Opportunity”
Danaher The Quiet Achiever With COVID-19 Vaccines and Therapeutics
Danaher is a name not often linked to the Coronavirus vaccine industry. In fact, DHR has been entrenched in the development of COVID-19 vaccines and therapeutics through its $21.4 billion acquisition of Cytiva last March and raised its Q1 guidance to the high end. Image: Danaher Cytiva Lab Danaher is forecasting core revenue growth to be above the high-end of its previous guidance range as the life sciences and medical diagnostic tools and instruments it manufactures continue to receive order way above … Continue reading “Danaher The Quiet Achiever With COVID-19 Vaccines and Therapeutics”